|
Orthologous residues
|
|
PZR (human): Y241‑p, PZR iso3 (human): ‑, PZR (mouse): Y242‑p, PZR iso3 (mouse): ‑, PZR (rat): Y242‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], A431 (epithelial), HeLa (cervical), HepG2 (hepatic), HT1080 (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Src (human)
|
transfection of constitutively active enzyme, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
ConA
|
|
|
|
increase
|
|
|
PP1
|
ConA
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
cell adhesion, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
SHP-2 (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|